Related Experiment Videos
Insights
Juvenile dermatomyositis (JDMS) is a distinct childhood inflammatory disease. Research suggests genetic predisposition and explores its unique immunologic and pathological features.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Genetics
Background:
- Childhood myositis presents with muscle enzyme elevation, weakness, and inflammation.
- Juvenile dermatomyositis (JDMS) is more common than polymyositis (PM) in children, especially females, and features skin involvement.
- Steroid treatment has significantly reduced JDMS mortality, but calcifications remain a debilitating issue.
Purpose of the Study:
- To establish Juvenile dermatomyositis (JDMS) as a distinct disease entity.
- To investigate potential genetic predispositions, such as HLA-B8 and DR3, in JDMS.
- To explore the immunologic abnormalities and pathogenetic factors in JDMS.
Main Methods:
- Review of clinical characteristics, including cutaneous involvement and demographics.
- Analysis of immunologic markers: natural killer cell activity, complement activation, ANA, and coxsackie B antibodies.
- Examination of pathological findings, including endothelial cell inclusions and small vessel occlusion.
Main Results:
- JDMS is proposed as a distinct entity, potentially influenced by genetic factors (HLA-B8, DR3).
- Immunologic findings include impaired natural killing, complement activation, and positive ANA; Jo-1 antibodies are absent.
- Pathology reveals endothelial cell inclusions linked to small vessel occlusion and elevated Factor VIII in active disease.
Conclusions:
- JDMS is a distinct disease with potential genetic links.
- Understanding JDMS immunopathogenesis requires further investigation into immune cell dysfunction and viral associations.
- Effective treatment strategies, including steroids and other immunosuppressants, require rigorous evaluation for severely affected children.
Abstract:
Myositis in childhood is characterized by elevated serum levels of muscle-derived enzymes, proximal symmetrical muscle weakness, abnormal EMG findings, and a muscle biopsy, which frequently documents an inflammatory process. In the pediatric age group, JDMS, which has characteristic cutaneous involvement in addition to myositis, is much more common than PM and is more common among female patients. With the use of steroids, mortality has been reduced from 33 per cent to 7 per cent. The development of calcifications can be the most debilitating consequence of JDMS. It is our premise that JDMS is a distinct disease entity and that the increase in HLA-B8 and DR3 in JDMS suggests that genetic background may predispose to disease development. There are conflicting data concerning immunologic abnormalities in JDMS, but there appears to be impairment of natural killing and evidence of complement activation. Results of tests for ANA frequently are positive in JDMS, but Jo-1 antibody, found in some adults with PM, has not been found in JDMS. Most newly diagnosed JDMS patients have antibodies to coxsackie B that may be related to the pathogenesis of this disease. Specific pathologic findings of endothelial cells containing reticulotubular inclusions are associated with small vessel occlusion, subsequent obliteration, and increased factor VIII levels in clinically active disease. In addition to physical therapy, steroids are used most frequently, but other immunosuppressive agents and plasmapheresis have been tried in severely ill children. Rigorous evaluation of the efficacy of these modalities is needed.